Summary
Adalimumab treatment of psoriasis patients following suboptimal responses to etanercept, methotrexate, or phototherapy: Efficacy across subgroups in an open-label study
Summary
Response to adalimumab in psoriasis patients previously treated with anti-tumor necrosis factor agents: Subanalysis of BELIEVE
Summary
Efficacy and safety of adalimumab in patients with psoriasis treated continuously for over 3 years
Summary
Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Summary
Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Summary
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial
Summary
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
Summary
A double blind study in pediatric subjects with chronic plaque psoriasis, studying adalimumab vs. Methotrexate (NCT01251614)
Summary
Adalimumab plus topical treatment (calcipotriol/betamethasone) in the treatment of moderate to severe psoriasis: Response across subgroups in BELIEVE
Summary
Long-term outcomes of interruption andretreatment versus continuous therapy with adalimumab for psoriasis subanalysis REVEAL
This site complies with the HONcode standard for trustworthy health information: